Axsome Therapeutics (AXSM) Received its Third Buy in a Row

After BTIG and Mizuho Securities gave Axsome Therapeutics (NASDAQ: AXSM) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Myles Minter maintained a Buy rating on Axsome Therapeutics yesterday. The company’s shares closed last Friday at $61.34.

According to, Minter is a 4-star analyst with an average return of 12.4% and a 50.8% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $135.83, implying an 119.7% upside from current levels. In a report issued on May 26, Morgan Stanley also maintained a Buy rating on the stock with a $105.00 price target.

See today’s analyst top recommended stocks >>

Axsome Therapeutics’ market cap is currently $2.32B and has a P/E ratio of -22.70. The company has a Price to Book ratio of 23.63.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts